Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Yaping Zhang, Xinfeng Wang, Yifei Liu, Chunfeng Sun, Wenyu Shi & Hongming Huang. (2018) Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: A promising response and review. Cancer Biology & Therapy 19:7, pages 549-553.
Read now
Read now
Erika Vacchelli, Fernando Aranda, Norma Bloy, Aitziber Buqué, Isabelle Cremer, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2016) Trial Watch—Immunostimulation with cytokines in cancer therapy. OncoImmunology 5:2.
Read now
Read now
Ibrahim H. Younos, Fuminori Abe & James E. Talmadge. (2015) Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets. Leukemia & Lymphoma 56:8, pages 2251-2263.
Read now
Read now
Norma Bloy, Aitziber Buqué, Fernando Aranda, Francesca Castoldi, Alexander Eggermont, Isabelle Cremer, Catherine Sautès-Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2015) Trial watch: Naked and vectored DNA-based anticancer vaccines. OncoImmunology 4:5.
Read now
Read now
Florine Obrist, Gwenola Manic, Guido Kroemer, Ilio Vitale & Lorenzo Galluzzi. (2015) Trial Watch: Proteasomal inhibitors for anticancer therapy. Molecular & Cellular Oncology 2:2.
Read now
Read now
Jonathan Pol, Erika Vacchelli, Fernando Aranda, Francesca Castoldi, Alexander Eggermont, Isabelle Cremer, Catherine Sautès-Fridman, Jitka Fucikova, Jérôme Galon, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2015) Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. OncoImmunology 4:4.
Read now
Read now
Aitziber Buqué, Norma Bloy, Fernando Aranda, Francesca Castoldi, Alexander Eggermont, Isabelle Cremer, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Aurélien Marabelle, Radek Spisek, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2015) Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. OncoImmunology 4:4.
Read now
Read now
Erika Vacchelli, Jonathan Pol, Norma Bloy, Alexander Eggermont, Isabelle Cremer, Wolf Hervé Fridman, Jérôme Galon, Aurélien Marabelle, Holbrook Kohrt, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2015) Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. OncoImmunology 4:1.
Read now
Read now
Lorenzo Galluzzi, Guido Kroemer & Alexander Eggermont. (2014) Novel immune checkpoint blocker approved for the treatment of advanced melanoma. OncoImmunology 3:11.
Read now
Read now
Jonathan Pol, Norma Bloy, Florine Obrist, Alexander Eggermont, Jérôme Galon, Isabelle Cremer, Philippe Erbs, Jean-Marc Limacher, Xavier Preville, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch:. OncoImmunology 3:6.
Read now
Read now
Fernando Aranda, Erika Vacchelli, Florine Obrist, Alexander Eggermont, Jérôme Galon, Wolf Hervé Fridman, Isabelle Cremer, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:5.
Read now
Read now
Erika Vacchelli, Fernando Aranda, Alexander Eggermont, Jérôme Galon, Catherine Sautès-Fridman, Isabelle Cremer, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:3.
Read now
Read now
Michaela Semeraro & Lorenzo Galluzzi. (2014) Novel insights into the mechanism of action of lenalidomide. OncoImmunology 3:2.
Read now
Read now
Fernando Aranda, Erika Vacchelli, Alexander Eggermont, Jérôme Galon, Wolf Hervé Fridman, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:2.
Read now
Read now
Erika Vacchelli, Fernando Aranda, Alexander Eggermont, Jérôme Galon, Catherine Sautès-Fridman, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:1.
Read now
Read now
Articles from other publishers (29)
Claudia Felici, Anna Passarelli, Paola Cafforio, Vito Racanelli, Patrizia Leone & Marco Tucci. (2023) Lenalidomide arrests cell cycle and modulates PD1-dependent downstream mTOR intracellular signals in melanoma cells. Melanoma Research 33:5, pages 357-363.
Crossref
Crossref
Soumik Das, Achsha Babu, Tamma Medha, Gnanasambandan Ramanathan, Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Reshma Murali, Sandra Kannampuzha, Abilash Valsala Gopalakrishnan, Kaviyarasi Renu, Debottam Sinha & C. George Priya Doss. (2023) Molecular mechanisms augmenting resistance to current therapies in clinics among cervical cancer patients. Medical Oncology 40:5.
Crossref
Crossref
Pugazhenthan Thangaraju, Sree Sudha Tanguturi Yella, Siva Sanker Reddy Lingareddygari & Kota Sesha Brahma Shree Krishna Sasanka. (2022) Repurposing Thalidomide, its Analogue and Apremilast for Possible
Antiviral in Situation of Severe COVID Cytokine Syndrome. Infectious Disorders - Drug Targets 22:8.
Crossref
Crossref
Rami M. Alzhrani, Atiah H. Almalki, Saleh l. Alaqel & Sameer Alshehri. (2022) Novel numerical simulation of drug solubility in supercritical CO2 using machine learning technique: Lenalidomide case study. Arabian Journal of Chemistry 15:11, pages 104180.
Crossref
Crossref
Hao Guo, Jingyi Yang, Haoran Wang, Xingchen Liu, Yanyan Liu & Keshu Zhou. (2022) Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. Frontiers in Immunology 13.
Crossref
Crossref
Chen-Lu Geng, Jun-Yi Chen, Tian-Yu Song, Jae Hyung Jung, Min Long, Min-Fang Song, Tong Ji, Byung Soh Min, Jin Gu Lee, Bo Peng, Yi-Sheng Pu, Hong-Jie Fan, Piliang Hao, Qi Zhou, Eui-Cheol Shin & Yong Cang. (2022) Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling. Cell Chemical Biology 29:8, pages 1260-1272.e8.
Crossref
Crossref
A. Calugareanu, F. Cordoliani, M. Battistella, M.-D. Vignon-Pennamen, C. Lepelletier, M. Bagot, J.-D. Bouaziz, J.-C. Auffranc, M. Jachiet & A. Petit. (2021) Plasmocytose cutanée avec signe de Darier chez une femme d’ascendance européenne. Annales de Dermatologie et de Vénéréologie - FMC 1:7, pages 477-481.
Crossref
Crossref
A. Calugareanu, F. Cordoliani, M. Battistella, M.-D. Vignon-Pennamen, C. Lepelletier, M. Bagot, J.-D. Bouaziz, J.-C. Auffranc, M. Jachiet & A. Petit. (2020) Plasmocytose cutanée avec signe de Darier chez une femme d’ascendance européenne. Annales de Dermatologie et de Vénéréologie 147:8-9, pages 552-557.
Crossref
Crossref
Claudia Pellacani & Georgios Eleftheriou. (2020) Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies. Advances in Medical Sciences 65:2, pages 265-285.
Crossref
Crossref
Athar Khalil, Amina Kamar & Georges Nemer. (2020) Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing?. Frontiers in Immunology 11.
Crossref
Crossref
Zhixiong Wang, Guomin Zhou, Na Risu, Jiayu Fu, Yan Zou, Jiaxing Tang, Long Li, Hui Liu, Qian Liu & Xuekai Zhu. (2020) Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells. Cell Transplantation 29, pages 096368972092082.
Crossref
Crossref
Pooja Sabhachandani, Saheli Sarkar, Seamus Mckenney, Dashnamoorthy Ravi, Andrew M. Evens & Tania Konry. (2019) Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release. Journal of Controlled Release 295, pages 21-30.
Crossref
Crossref
Manon Bosseler, Vanessa Marani, Angelina Broukou, Amandine Lequeux, Tony Kaoma, Vincent Schlesser, Jean-Hugues François, Valérie Palissot, Guy Berchem, Nasséra Aouali & Bassam Janji. (2018) Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy. International Journal of Molecular Sciences 19:6, pages 1551.
Crossref
Crossref
N. V. Khatri, B. Patel, D. R. Kohli, S. S. Solomon, K. Bull‐Henry & C. M. Kessler. (2018) Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease. Haemophilia 24:2, pages 278-282.
Crossref
Crossref
Brigitte Neuber, Jingying Dai, Wjahat A. Waraich, Mohamed H.S. Awwad, Melanie Engelhardt, Michael Schmitt, Sergej Medenhoff, Mathias Witzens-Harig, Anthony D. Ho, Hartmut Goldschmidt & Michael Hundemer. (2017) Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28− T-cells. Oncotarget 8:58, pages 98200-98214.
Crossref
Crossref
Li Yin, Ashujit Tagde, Reddy Gali, Yu-Tzu Tai, Teru Hideshima, Kenneth Anderson, David Avigan & Donald Kufe. (2017) MUC1-C is a target in lenalidomide resistant multiple myeloma. British Journal of Haematology 178:6, pages 914-926.
Crossref
Crossref
Alejandro López-Soto, Segundo Gonzalez, Mark J. Smyth & Lorenzo Galluzzi. (2017) Control of Metastasis by NK Cells. Cancer Cell 32:2, pages 135-154.
Crossref
Crossref
Massimo Giuliani, Bassam Janji & Guy Berchem. (2017) Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Oncotarget 8:14, pages 24031-24044.
Crossref
Crossref
Belen Lopez-Millan, Rafael Diaz de la Guardia, Heleia Roca-Ho, Carmen M García-Herrero, Jessie R Lavoie, Michael Rosu-Myles, Elena Gonzalez-Rey, Francisco O'Valle, Gabriel Criado, Mario Delgado & Pablo Menendez. (2017) Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease. Experimental & Molecular Medicine 49:2, pages e290-e290.
Crossref
Crossref
Valérie PourcherAude DesnoyerLambert AssoumouCéleste LebbeAngélique CurjolAnne-Geneviève MarcelinFanny CardonSéverine GibowskiDominique SalmonJean-Marie ChennebaultIsabelle Poizot-MartinGilles PeytavinFrançois BouéDominique Costagliola. (2017) Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial. AIDS Research and Human Retroviruses 33:1, pages 1-10.
Crossref
Crossref
Matevz Skerget, Barbara Skopec, Darja Zontar & Peter Cernelc. (2016) Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Radiology and Oncology 50:4, pages 402-408.
Crossref
Crossref
Takashi IshidaHiroshi FujiwaraKisato NosakaNaoya TairaYasunobu AbeYoshitaka ImaizumiYukiyoshi MoriuchiTatsuro JoKenichi IshizawaKensei TobinaiKunihiro TsukasakiShigeki ItoMakoto YoshimitsuMaki OtsukaMichinori OguraShuichi MidorikawaWanda RuizTomoko Ohtsu. (2016) Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. Journal of Clinical Oncology 34:34, pages 4086-4093.
Crossref
Crossref
Claudia Zelle-Rieser, Shanmugapriya Thangavadivel, Rainer Biedermann, Andrea Brunner, Patrizia Stoitzner, Ella Willenbacher, Richard Greil & Karin Jöhrer. (2016) T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. Journal of Hematology & Oncology 9:1.
Crossref
Crossref
SHENG FANG, KUI SHAN & AI-JUN CHEN. (2016) Cutaneous and systemic plasmacytosis on the face: Effective treatment of a case using thalidomide. Oncology Letters 11:3, pages 1923-1925.
Crossref
Crossref
Cinzia Fionda, Maria Pia Abruzzese, Alessandra Zingoni, Francesca Cecere, Elisabetta Vulpis, Giovanna Peruzzi, Alessandra Soriani, Rosa Molfetta, Rossella Paolini, Maria Rosaria Ricciardi, Maria Teresa Petrucci, Angela Santoni & Marco Cippitelli. (2015) The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. Oncotarget 6:27, pages 23609-23630.
Crossref
Crossref
L. Apetoh, S. Ladoire, G. Coukos & F. Ghiringhelli. (2015) Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?. Annals of Oncology 26:9, pages 1813-1823.
Crossref
Crossref
Laurence Zitvogel, Lorenzo Galluzzi, Oliver Kepp, Mark J. Smyth & Guido Kroemer. (2015) Type I interferons in anticancer immunity. Nature Reviews Immunology 15:7, pages 405-414.
Crossref
Crossref
Anna Domogala, J. Alejandro Madrigal & Aurore Saudemont. (2015) Natural Killer Cell Immunotherapy: From Bench to Bedside. Frontiers in Immunology 6.
Crossref
Crossref
Mohammad Hojjat-Farsangi. (2015) Novel and emerging targeted-based cancer therapy agents and methods. Tumor Biology 36:2, pages 543-556.
Crossref
Crossref